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BACKGROUND: In 2007, an Asthma/chronic obstructive pulmonary disease (COPD) (AC) service was implemented in the North of
the Netherlands to support General Practitioners (GPs) by providing advice from pulmonologists on a systematic basis.
AIMS: To evaluate the feasibility and effectiveness of this service on patient-related outcomes.
METHODS: We report baseline data on 11,401 patients and follow-up data from 2,556 patients. GPs can refer all patients with
possible obstructive airway disease (OAD) to the service, which is conducted by the local laboratory. Patients are assessed in the
laboratory using questionnaires and spirometry. Pulmonologists inspect the data through the internet and send the GP diagnosis
and management advice.
RESULTS: A total of 11,401 patients were assessed by the service, covering almost 60% of all adult patients with projected asthma
or COPD in the area. In all, 46% (n= 5,268) of the patients were diagnosed with asthma, 18% (n= 2,019) with COPD and 7% (n= 788)
with the overlap syndrome. A total of 740 (7%) patients were followed up after 3 months because the GP advised them to change
medication. In this group, the proportion of unstable COPD patients (Clinical COPD Questionnaire (CCQ)⩾ 1) decreased from 63%
(n= 92) at baseline to 49% (n= 72). The proportion of patients with uncontrolled asthma (Asthma Control Questionnaire
(ACQ)⩾ 1.5) decreased from 41% (n= 204) to 23% (n= 115). In all, 938 (8%) patients were followed up after 12 months. From these
patients, the proportion of unstable COPD patients (CCQ⩾ 1) decreased from 47% (n= 115) to 44% (n= 107). The proportion of
patients with uncontrolled asthma (ACQ⩾ 1.5) decreased from 16% (n= 95) to 14% (n= 85).
CONCLUSION: The AC service assessed a considerable proportion of patients with OAD in the area, improved patients’ outcomes,
and is considered to be feasible and effective.
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INTRODUCTION
Asthma and chronic obstructive pulmonary disease(COPD) are
prevalent chronic diseases in the community.1 In the Netherlands,
60 to 80% of all asthma and COPD patients are treated by their
general practitioner (GP), and patients are only referred to the
pulmonologist in case of severe uncontrolled asthma or severe
COPD.2 Misdiagnosis and underdiagnosis are common,3–5 as
asthma and COPD overlap in symptoms, whereas their treatments
are different.6 Some patients have both asthma and COPD, the so-
called overlap syndrome, which can be described as (partly)
reversible but progressive deterioration in lung function, often
combined with a history of smoking and previous diagnosis of
asthma and/or allergies. These diagnostic problems may lead to
suboptimal treatment, whereas early correct treatment can reduce
costs, morbidity and mortality, can improve symptoms and
enhance patient outcomes.3–5,7
In daily clinical practice, many GPs often lack the knowledge,
time and enthusiasm to perform all tasks that are recommended
by guidelines. For example, Dutch GPs are obliged to follow 96
guidelines for common diseases, of which only three are
concerned with asthma, asthma in children, and COPD.8–10 GPs
therefore could benefit from the knowledge and experience of
pulmonologists by obtaining advice for each patient with
pulmonary symptoms. Cooperation between GPs and other
caregivers in integrated care projects for COPD patients has been
proven to be effective in improving the quality of life and health
status of patients, thus reducing costs and the number of
hospitalisations.11,12 Asthma/COPD services in which GPs are
supported by pulmonologists in interpreting spirometry results
are feasible and might improve diagnostic accuracy.13 GPs and
pulmonologists in the North of the Netherlands collaborated and
implemented the Asthma/COPD (AC) service in 2007 as a support
service for GPs. The aim of this service is to improve the
management of asthma and COPD patients in primary care.
Although the service was not developed for scientific reasons,
data from included patients are available for research. This paper
describes the development and feasibility of this service, the
patient population and its effect on patient-related outcomes.
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MATERIALS AND METHODS
Design and feasibility
Meetings with local physicians were organised, resulting in four starting
principles: (1) the service should optimise diagnosis, treatment and
management; (2) the GP is in lead; (3) the service should be easily
accessible for patients and physicians; (4) allocation of tasks between
primary and secondary care have to be defined clearly.14 Yearly meetings
are organised to inform physicians about current developments, discuss
casuistry and enhance commitment.
The role of the GP. GPs can refer individual patients (⩾ 8 years of age) who
are suspected to have asthma, COPD, overlap syndrome or present with
pulmonary symptoms of unknown origin further referred to as obstructive
airway disease (OAD). The GP can also choose to refer all OAD patients in
his/her practice on the basis of inhaled medication use and/or courses of
prednisolone. When preferred by the GP, referral may also include follow-
up assessments by the AC service. Finally, the GP decides what to do with
the advice of the pulmonologist and is responsible for the disease
management.
Self-reported information by patients. Patients complete the ‘Asthma
Control Questionnaire (ACQ),’ the ‘Clinical COPD Questionnaire (CCQ)’ and
a medical history questionnaire assessing gender, age, age of onset, family
history, symptoms, exacerbations (having used oral corticosteroids or
antibiotics for lung problems), allergy and other stimuli-provoking
symptoms, medication, occupation and smoking history as part of the
regular assessment procedure.
The ACQ is used to measure asthma control and contains six questions
(range 0–6), and the total score can be divided into ‘controlled’ (o0.75),
‘partially controlled’ (0.75–1.50) and ‘uncontrolled’ (⩾ 1.50).14 The CCQ is
used to measure COPD health status, and it contains 10 questions. The
total score (range 0–6) can be distributed between ‘stable’ (o1), ‘not
entirely stable’,1,2 ‘unstable’2,3 and ‘very unstable’ (⩾ 3). This questionnaire
contains three subdomains with four questions about functional status,
four questions about symptoms and two questions about mental
status.14,15
Assessment by the trained lung function technician. The assessments take
place in local laboratories according to a strict protocol. The following
measurements are taken:
● Body mass index.
● Evaluation and, if needed, instruction of the inhalation technique
according to the Dutch ‘Inhalation Medication Instruction School’
guidelines.
● Spirometry according to international guidelines.16
All data, including the scores on the questionnaires, are inserted in an
Electronic Diagnostic Support (EDS) system.
The role of the pulmonologist. Pulmonologists are trained in using the
service by following at least two training sessions. In this paper, we
included pulmonologists who had assessed ⩾ 300 patients to avoid the
influence of learning effects. Pulmonologists assess the quality of the
spirometry, inspect all outcomes in the Electronic Diagnostic Support
system and make a report (based on current international guidelines2,17)
with diagnosis, follow-up and treatment advice. Treatment advice can
include lifestyle advice (e.g., dietician, smoking cessation or physical
activity) or medication change. Pulmonologists were not provided with
strict diagnostic rules. The GPs receive the report from the pulmonologist
within 5 working days through the internet directly in their patient
information system.
Statistical data analyses
IBM-SPSS version 22 was used for statistical analysis. The baseline
population was described by age, gender, body mass index, exacerbation
history, smoking history, lung function performances, diagnosis and GOLD
2013 category (A, B, C and D).17 A positive bronchodilator response was
defined as an increase in forced expiratory volume in 1 s (FEV1) of ⩾ 12%
and ⩾ 200ml. The median scores of GOLD A, B, C and D patients on the
CCQ subscales are presented.
Feasibility analyses. Feasibility was assessed by analysing the following:
(1) the proportion of GPs in the target area who used the AC service
between 2007 and 2012; (2) the proportion of patients with asthma or
COPD who were assessed by the service in the target area since 2007;18
(3) the quality of the spirometry; (4) the number of patients that could be
diagnosed, and the variation in diagnostic pattern between the different
pulmonologists by using chi-square.
Follow-up visits. Patients for whom medication change was advised by
the pulmonologist were automatically scheduled for an additional follow-
up assessment after 3 months (range 2–4 months, n= 740). If the GP
requested follow-up visits and no medication change was advised, patients
were assessed after 12 months (range 10–14, n= 938). Baseline data of
adult patients on exacerbations/year, smoking status, inhalation technique,
ACQ and CCQ scores were compared with follow-up data. Nonparametric
paired tests were used to compare baseline data with follow-up data.
Paired t-tests were used for the longitudinal evaluation of FEV1(in litres).
Follow-up data of baseline GOLD stages are presented to show the
distribution of these patients to other GOLD stages.17 To prevent overlap in
our results, we excluded patients with 41 follow-up assessment in 1 year
(n=79).
RESULTS
Baseline patient characteristics are presented in Tables 1 and 2.
Feasibility
The service included around 2,000 (range: 1,813–2,109) new
patients yearly from 79.3% of the GPs in the target area.
Approximately 50% of patients were included by practice screen-
ing. In all, 60% of all adult asthma and COPD patients in the target
area were assessed at least once by the AC service.18,19
Pulmonologists considered the quality of 93.6% of the spirometry
graphs to be usable for diagnosis and could diagnose 79.4% of the
patients (asthma: 45.8%, COPD: 17.8%, overlap syndrome: 6.9%).
See Supplementary 1 for an overview of COPD GOLD A, B, C and D
patients at baseline. Baseline diagnosis was compared with follow-
up diagnosis, and it did not change during the follow-up in 91.2%
(confidence interval: 89.4–92.7%) of baseline asthma patients, in
87.7% (confidence interval: 84.4–90.4%) of baseline COPD patients
and in 74.2% (confidence interval: 68.0–79.5%) of baseline overlap
syndrome patients. There was variation in diagnostic pattern in
adult patients between the different pulmonologists (n= 10,
Po0.000); see Figure 1.
Follow-up visits
Patients frequently changed from GOLD (2013) category, and
many GOLD D patients (n= 74) moved to other GOLD categories
at follow-up (Follow-up category: GOLD A: 21.6%, B: 36.5%,
C: 6.8%, D: 35.1%); see Figure 2.
Patients advised to change medication (Patients followed-up after 3
months, total = 740). Inhalation technique improved significantly
(correct at baseline 35.1% to 52.5% after 3 months, n total = 459,
Po0.000). The proportion of well-controlled asthma patients
increased from 23.9% (baseline) to 49.5% (3 months, n total = 487,
Po0.000), and the proportion of stable COPD patients increased
from 27.4% (baseline) to 48.9% (3 months, n total = 145, P= 0.004).
The proportion of GOLD D patients decreased from 12.8% at
baseline to 6.7% after 3 months; see Table 3 (n total = 145,
Po0.000).
Patients advised to continue current medication (Patients followed-
up after 12 months, n = 938). Inhalation technique did improve
significantly (correct baseline 37.4 to 49.9% after 12 months,
n= 741, Po0.000). The proportion of current smokers decreased
from 25.2% at baseline to 23.2% after 12 months (n= 984,
P= 0.013). The proportion of asthma and COPD patients with ⩾ 1
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exacerbation last year decreased (asthma: 35.0% at baseline,
25.2% at 12 months, P40.000; COPD: 34.8% at baseline, 25.4% at
12 months, P= 0.010); see Table 4.
DISCUSSION
Main findings
In this study, we have evaluated over 11,000 patients referred by
360 different GPs to the Asthma/COPD (AC) service in the North of
the Netherlands. With 60% of all asthma and COPD patients in the
area participating, the service is well implemented in the target
area. We chose to report the follow-up results from patients who
were advised to change medication after 3 months separately
from the patients who were advised to continue with their
medication and were scheduled to have a 12-month follow-up. If a
change in medication was advised, after 3 months, health status
improved in COPD patients and asthma control improved in
asthma patients. Asthma and COPD patients who did not need
medication change and were referred to the yearly follow-up
assessment stabilised in asthma control and in COPD health
status. Overlap syndrome patients in this group improved in
asthma control and health status. Most (65%) of the GOLD D
patients moved to other categories after baseline visit; some of
these patients (22%) even improved to GOLD category A. Given
these results, we consider the AC service to be a feasible and
effective collaboration service for primary and secondary care.
Interpretation of findings in relation to previously published work
According to the Global Initiative for Asthma guidelines,
uncontrolled asthma patients would be eligible for referral to
Table 1. Baseline characteristics of the total patient population in the
AC tele-medicine service
Variable Total group, n= 11,401
Diagnosis of n (%)
COPD 2,031 (17.8)
Very unstable (CCQ⩾ 3) 161 (8.0)
Asthma 5,223 (45.8)
Uncontrolled (ACQ⩾ 1.50) 2,049 (39.3)
Asthma/COPD overlap syndrome 787 (6.9)
Very unstable (CCQ⩾ 3) 77 (9.9)
Uncontrolled (ACQ⩾ 1.50) 308 (39.4)
Indication for restriction 159 (1.4)
No lung disease 796 (7.0)
Unclear diagnosis 2,354 (20.6)
Missing at random 15 (0.1)
Diagnosis is unclear because of n (%)
Incorrect lung function test 297 (12.6)
Unknown 2,057 (87.4)
Referral to pulmonologist because of n (%)
Unclear diagnosis 1,966 (54.7)
Indication of restriction 18 (0.005)
Unable to perform lung function test 18 (0.005)
COPD 558 (15.5)
FEV1 o50% predicted 302 (54.3)
Asthma/COPD overlap syndrome 214 (6.0)
FEV1 o50% predicted 27 (12.7)
Asthma 690 (19.2)
Unstable (ACQ⩾ 1.50) 469 (68.2)
Total 3,593 (31.5)
Quality lung function test n (%)
Sufficient 10,670 (93.6)
Insufficient 730 (6.4)
In 31.5% of the assessments, the pulmonologist advised the GP to refer
their patient to secondary care mostly because of unclear diagnosis
(54.7%). Most patients with unclear diagnosis (age, 51± 19; age of onset,
39± 23; 42% male) had no obstruction (FEV1/FVC⩾ 70%: 90%), no positive
bronchodilator response (93%) and no allergy (76%). However, these
patients were high in symptoms (CCQ⩾ 1: 68%).
Abbreviations: AC, asthma/COPD; ACQ, Asthma Control Questionnaire;
CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary
disease; FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; GP, general practitioner.
Table 2. Baseline characteristics of the patient population per
diagnosis
Variable COPD,
n= 2,031
Overlap
syndrome,
n= 787
Asthma,
n= 5,223
Gender and age n (%) n (%) n (%)
Male 1,190 (58.6) 388 (49.3) 2,007 (38.4)
Self-reported ⩾ 1
allergy
243 (12.0) 312 (39.6) 2,658 (50.9)
Mean (s.d.) Mean (s.d.) Mean (s.d.)
Age, years 66.6 (10.8) 60.6 (12.3) 43.6 (18.7)
Age of onset, years 52.2 (19.6) 33.6 (23.1) 22.3 (19.6)
Body mass index (kg/
m2)
26.6 (4.8) 27.1 (4.9) 26.7 (6.0)
Exacerbations in the
last 12 months
0.7 (1.1) 0.9 (1.2) 0.8 (1.2)
Lung function post bronchodilator, mean (s.d.)
FEV1 (L) 2.0 (0.7) 2.3 (0.7) 3.1 (0.9)
FEV1% predicted 69.0 (18.1) 76.0 (15.5) 94.6 (15.1)
FVC (L) 3.6 (1.0) 3.7 (1.1) 4.0 (1.1)
FVC % predicted 98.6 (18.4) 102.1 (17.2) 101.1 (16.3)
FEV1/FVC 56.0 (11.2) 61.0 (9.5) 79.3 (8.8)
Reversibilitya 6.4 (7.9) 11.2 (10.0) 6.7 (7.6)
Positive BDTb adults, n (%)
Post FEV1/FVCo70% 198 (99.0) 236 (91.5) 204 (25.0)c
Post FEV1/
FVC= 70–80%
2 (1.0) 22 (8.5) 358 (43.8)
Post FEV1/
FVC= 80–90%
214(26.2)
Post FEV1/FVC⩾ 90% 40 (4.9)
Total 200 (10.7) 258 (34.8) 817 (16.6)
Inhalation techniquea, n (%)
Correct 325 (36.1) 205 (36.5) 1,434 (38.0)
Incorrect 576 (63.9) 357 (63.5) 2,339 (62.0)
Smoking history (age⩾ 18 years), n (%)
Smoking history
missing
8 (0.4) 0 (0.0) 17 (0.4)
Never smoked 70 (3.4) 54 (6.9) 2,041 (43.4)
Quit ⩾ 12 months ago 948 (46.7) 378 (48.0) 1,628 (34.6)
Current smoker 1,005 (49.5) 355 (45.1) 1,014 (21.6)
Males 517 (51.4) 151 (42.5) 383 (37.8)
Males motivated to
quit
304 (58.8) 89 (58.9) 231 (60.3)
Females 475 (47.3) 197 (55.5) 614 (60.6)
Females motivated
to quit
295 (62.1) 112 (56.8) 407 (66.3)
Abbreviations: BDT, bronchodilator test; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in one second; FVC,
forced vital capacity.
aIncrease in FEV1 pre bronchodilator compared with FEV1 post broncho-
dilator.
bPositive bronchodilator response test defined as a reversible lung
function of ⩾ 200 ml and ⩾ 12% increase in FEV1 pre bronchodilator
compared with FEV1 post bronchodilator.
cAdult asthma patients (male: 59%, mean age: 52 years, 19% current
smokers) with obstruction before and after bronchodilator.
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secondary care.2 The prevalence of uncontrolled asthma patients
in our population (age ⩾ 16 years) is lower (40%) than the
prevalence found in the INSPIRE study where 51% of the patients
had uncontrolled asthma.20 Only 13% of our asthma patients were
advised to be referred to secondary care (see Table 1), meaning
that the pulmonologists did not follow the Global Initiative for
Asthma guidelines. However, we do not know whether the GP
followed the referral recommendation of the pulmonologist.
The accuracy of the diagnosis in Asthma/COPD support systems
is of pivotal importance. Lucas et al. showed previously that a
diagnosis based on paper patient data without life contact in an
AC service is comparable with diagnoses acquired by a face-to-
face consultation. The level of agreement on diagnoses between
paper data and face-to-face diagnoses was κ= 0.82,21 which
exceeded the level of inter-doctor agreement from the different
assessing pulmonologists (κ= 0.6422). We used comparable history
questions and spirometry as Lucas et al. used, and we assume that
the diagnostic accuracy will be comparable as in the study of
Lucas et al. Diagnoses during follow-up visits in our AC service (see
Figure 1) showed that most of the diagnoses were consistent.
Although diagnoses are to some extent subjective, the advantage
of the system is that the GP can compare his own choices with the
diagnoses and advices from the pulmonologist. We believe that
this internet-based consultation in the long run might improve
skills in the management of OADs.
Van den Bemt et al.23 presented a service for COPD patients and
concluded that it was not clinically effective. However, their
population consisted of already-diagnosed COPD patients, and all
patients had performed spirometry previously to inclusion,
whereas we followed up both previously diagnosed and newly
diagnosed patients. We speculate that the room for improvement
in our population of a wide range of patients was higher, which
might have contributed to the positive effect. Furthermore,
internet is used for data exchange, and GPs receive the report
from the pulmonologist mostly within 5 working days electro-
nically in their patient information system, which makes the
service user friendly. Next to that, the use of Internet and the
trained lung function technicians make the service cost-effective.
Direct costs were covered by reimbursement for the spirometry in
primary care, including the involvement of the pulmonologist.
Generalisability. Our asthma patients differed from COPD
patients, whereas the characteristics of overlap syndrome patients
fell between asthma and COPD patients. This was also described
by Postma et al.24 who showed that asthma patients are younger,
more frequently female and have less frequently a history of
smoking. Miravitlles et al.25 showed the same pattern of patient
characteristics in their primary care population, although the
proportion of male patients in their overlap syndrome population
was much lower than in the AC population (Miravitlles: 26%, AC
service: 49%). Characteristics of our asthma patients (⩾16 years)
were comparable with asthmatics from the INSPIRE study
(AC service: male, 38%; mean age, 46 ± 17 years; current smokers,
21%. INSPIRE: male 35%; mean age, 45 ± 17 years; current
smokers, 21%).
When considering overlap syndrome as a subtype of COPD, the
prevalence of overlap syndrome in our COPD population was 28%,
which is comparable to the prevalence found by Ställberg et al.26
(25%) but higher than the prevalence reported by Postma et al.
Figure 1. This picture shows the variation in diagnoses in adult
patients between the assessing pulmonologists. Most variation is
seen in the diagnoses of asthma and other (unclear diagnoses,
indication for restriction or no disease). The variation in diagnoses
between the pulmonologists was significant (Chi-square= 580,
n= 10,656, Po0.000).
Figure 2. Distribution of COPD patients at baseline (n (total)= 2,004) according to the new GOLD classification of airflow limitation. Apparent
is the large proportion of patients at risk: 22% of the COPD patients were classified as GOLD D. GOLD D patients have a high risk of
exacerbations combined with a high burden of disease.
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(13–20%).24 Our overlap patients have more frequent exacerba-
tions compared with the asthma and COPD patients, which
indicate that these patients are more at risk for future exacerba-
tions. This high risk was confirmed in other studies.24,27,28
Although these patients are more at risk, at baseline only the
CCQ scores reflect this poor health status (CCQ⩾ 3: COPD, 8%;
overlap syndrome, 10%). Overlap patients were assessed by using
the ACQ and the CCQ, because these questionnaires were part of
the regular assessment in the AC collaboration service. However,
no validated measurements are available to assess the health
status and disease control in overlap patients. COPD patients in
the AC service were distributed according to the GOLD guidelines
using CCQ cutoff value of41 (A: 28%, B: 40%, C: 8% and D: 24%).
Lange et al.29 distributed 6,628 Danish COPD patients using the
modified Medical Research Council and found another distribution
(A: 77%, B: 14%, C: 4% and D: 4%). Apart from the difference in
symptom assessment by using the CCQ instead of the modified
Medical Research Council, our COPD sample of primary care–
treated patients is obviously more at risk and has more symptoms
than the Danish general population.
Reversibility. Only 17% of our asthma patients had a positive
bronchodilator test (BDT) response.2 In asthma patients with good
lung function (FEV1/forced vital capacity (FVC) after bronchodilator
⩾ 90%), the proportion of patients with a positive BDT was 5%,
whereas in asthma patients with very poor lung function
(FEV1/FVC post bronchodilator o70%), this proportion was 40%.
Others have also shown that reversibility in asthmatic patients
depends on the severity of asthma as measured by the
impairment in lung function.30 Although COPD is considered to
be a nonreversible obstructive lung disease, 11% of our COPD
patients had a BDT response, and the average reversibility was 6%.
In the UPLIFT study, 50% of the COPD patients showed significant
reversibility.31 Obviously, real-life COPD populations differ from
selected populations, as confirmed by Kruis et al.32 Bronchodilator
response was more prevalent in COPD patients with severe
disease.24The highest proportion of patients with positive BDT
response was seen in the overlap syndrome patients (35%), which
is consistent with the GOLD and Global Initiative for Asthma
recommendations.33
Risk factors. The proportion of smoking COPD and overlap
syndrome patients (COPD: 50%, overlap syndrome: 45%) was
much higher than in the Dutch population, which is 27%, and also
higher than the COPD population presented by Warnier et al.34
(37%). Our definition of smokers might have contributed to the
higher proportion, because we considered quitters o12 months
ago as current smokers. The AC service does not provide any
Table 3. Longitudinal differences in lung function, exacerbations, health status and asthma control of patients assessed at baseline and after
3 months (range: 2–4 months, n total= 740)
Diagnosis n Baseline After 3 months P valuea
Asthma (n = 503) n (%) n (%)
⩾ 1 exacerbation last yearb 483 188 (38.9)
Current smoker 497 92 (18.5) 87 (17.5) NS
Sufficient inhalation techniquec 320 120 (37.5) 173 (54.1) o0.000
Well controlled (ACQo0.75) 497 119 (23.9) 246 (49.5) o0.000
Partially controlled (ACQ⩾ 0.75 and o1.50) 174 (35.0) 136 (27.4)
Uncontrolled (ACQ⩾ 1.50) 204 (41.0) 115 (23.1)
Mean (s.d.) Mean (s.d.)
FEV1 pre (L) 455 3.0 (0.9) 2.9 (0.9) o0.000
COPD (n = 148) n (%) n (%)
⩾ 1 exacerbation 148 60 (40.5)
Current smoker or quit o12 months ago 147 63 (42.9) 62 (42.2) NS
Sufficient inhalation techniquec 79 19 (24.1) 38 (48.1) NS
Stable (CCQo1) 147 55 (37.4) 75 (51.0) 0.004
Not entirely stable (CCQ⩾ 1 &o2) 64 (43.5) 48 (32.7)
Unstable (CCQ⩾ 2 and o3) 19 (12.9) 18 (12.2)
Very unstable (CCQ⩾ 3) 9 (6.1) 6 (4.1)
Mean (s.d.) Mean (s.d.)
FEV1 pre (L) 148 2.1 (0.6) 2.1 (0.6) NS
Overlap syndrome (n = 82) n (%) n (%)
⩾ 1 exacerbation 82 41 (50.0)
Current smoker or quit o12 months ago 82 33 (40.2) 34 (41.5) NS
Sufficient inhalation techniquec 58 21 (36.2) 29 (50.0) NS
Well controlled (ACQo0.75) 82 35 (42.7) 48 (58.5) NS
Partially controlled (ACQ⩾ 0.75 and o1.50) 30 (36.6) 19 (23.2)
Uncontrolled (ACQ⩾ 1.50) 17 (20.7) 15 (18.3)
Stable (CCQo1) 31 8 (25.8) 16 (51.6) 0.073
Not entirely stable (CCQ⩾ 1 &o2) 16 (51.6) 11 (35.5)
Unstable (CCQ⩾ 2 and o3) 7 (22.6) 2 (6.5)
Very unstable (CCQ⩾ 3) 0 (0.0) 2 (6.5)
Mean (s.d.) Mean (s.d.)
FEV1 pre (L) 81 2.3 (0.6) 2.3 (0.7) NS
Patients were referred to the 3-month follow-up assessment if change in medication was advised by the pulmonologist.
Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in one second; NS, not significant.
aP values are two-sided and P values ⩾ 0.10 are reported as ‘NS’.
bExacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.
cInhalation technique in patients who use medication at baseline.
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cessation intervention but informs the GP if their patients are
motivated to quit. The follow-up time of 12 months could not
reveal the number of quitters (412 months) as a result of the
possible intervention of the GP.
Like in other studies,35 many patients (64%) showed an
insufficient inhalation technique. Although the inhalation techni-
que improved after 3 (50%) and 12 months (47%) of follow-up
after our standard instruction as recommended in the Dutch
guidelines, it is debatable whether this instruction is sufficiently
effective. Further research on effective instruction seems to be
needed.
Strengths and limitations of this study
The strength of this study is the large population of primary care
OAD patients in real life and the strict protocol used to assess
these patients. A limitation is that the AC service was not
established for scientific reasons, resulting in limited follow-up
results, and data could not be compared with a control group.36
Therefore, we cannot rule out that results might have been
affected by regression to the mean, although regression to the
mean (measured by 1− ρ) is small;37 see Supplementary 2. We also
do not have data on mortality; however, on the basis of national
mortality data, we assume that 1.8% of the COPD patients have
died in 1 year. Leivseth et al.38 showed that there are no large
differences in mortality rates between GOLD A, B, C and D.
Therefore, we assume that missed mortality rates hardly affected
our COPD follow-up results.
Implications for future research, policy and practice
Relatively simple support for GPs in diagnosing and managing
patients with a chronic disease by specialists might result in
improved outcomes for these patients in the community.
Principles of the AC service might also be suitable in other
chronic diseases. The large electronic database from the AC
service provides unique opportunities for further research in
primary care patients with OADs.
Conclusion
The AC service is feasible, effective and efficient in supporting GPs
to diagnose and manage asthma, COPD and overlap syndrome
patients. The service stimulates cooperation between primary and
secondary care, and delivers support to patients locally which is
important in rural areas.
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Table 4. Longitudinal differences in lung function, exacerbations, health status and asthma control of patients referred by their GP to single or yearly
follow-up assessment after 12 months (range 10–14 months, n total= 991). Patients in this table were not assessed after 3 months
Diagnosis n Baseline After 12 months P valuea
Asthma (n = 598) n (%) n (%)
⩾ 1 exacerbationb 572 200 (35.0) 144 (25.2) o0.000
Current smokers or quit o12 months ago 595 88 (14.8) 81 (13.6) NS
Sufficient inhalation techniquec 471 185 (39.3) 251 (53.3) o0.000
Well controlled (ACQo0.75) 591 377 (63.8) 383 (64.8) NS
Partially controlled (ACQ⩾ 0.75 and o1.50) 119 (20.1) 123 (20.8)
Uncontrolled (ACQ⩾ 1.50) 95 (16.1) 85 (14.4)
Mean (s.d.) Mean (s.d.)
FEV1 pre (L) 596 3.1 (0.9) 3.0 (0.9) o0.000
COPD (n = 245) n (%) n (%)
⩾ 1 exacerbationb 244 85 (34.8) 62 (25.4) 0.010
Current smokers or quit o12 months ago 243 109 (44.9) 99 (40.7) 0.017
Sufficient inhalation techniquec 177 59 (33.3) 78 (44.1) 0.034
Stable (CCQo1) 243 128 (52.7) 136 (56.0) NS
Not entirely stable (CCQ⩾ 1 and o2) 79 (32.5) 74 (30.5)
Unstable (CCQ⩾ 2 &o3) 23 (9.5) 24 (9.9)
Very unstable (CCQ⩾ 3) 13 (5.3) 9 (3.7)
Mean (s.d.) Mean (s.d.)
FEV1 pre (L) 244 2.2 (0.7) 2.1 (0.6) o0.000
Overlap syndrome (n = 88) n (%) n (%)
⩾ 1 exacerbationb 88 34 (38.6) 25 (28.4) NS
Current smokers or quit o12 months ago 88 38 (43.2) 34 (38.6) 0.094
Sufficient inhalation techniquec 66 24 (36.4) 28 (42.4) NS
Well controlled (ACQo0.75) 87 37 (42.5) 48 (55.2) 0.032
Partially controlled (ACQ⩾ 0.75 and o1.50) 25 (28.7) 21 (24.1)
Uncontrolled (ACQ⩾ 1.50) 25 (28.7) 18 (20.7)
Stable (CCQo1) 65 24 (36.9) 30 (46.2) 0.027
Not entirely stable (CCQ ⩾ 1 & o2) 27 (41.5) 26 (40.0)
Unstable (CCQ⩾ 2 and o3) 7 (10.8) 7 (10.8)
Very unstable (CCQ⩾ 3) 7 (10.8) 2 (3.1)
Mean (s.d.) Mean (s.d.)
FEV1 pre (L) 88 2.3 (0.7) 2.2 (0.7) o0.000
Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in one second; GP, general practitioner; NS, not significant.
aP values are two-sided and P values ⩾ 0.10 are reported as ‘ns’.
bExacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.
cInhalation technique in patients who use medication at baseline.
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